Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ERY066
MIFTS: 30

Erythema Multiforme Major

Categories: Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Erythema Multiforme Major

About this section

MalaCards integrated aliases for Erythema Multiforme Major:

Name: Erythema Multiforme Major 58 6 71
Erythema Exsudativum Multiforme Majus 58
Erythema Multiforme Majus 58
Stevens-Johnson Syndrome 71

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
Orphanet: 58  
Rare skin diseases


External Ids:

Orphanet 58 ORPHA502499
UMLS 71 C0038325 C3241919
Sources

Summaries for Erythema Multiforme Major

About this section
MalaCards based summary : Erythema Multiforme Major, also known as erythema exsudativum multiforme majus, is related to erythema multiforme and severe cutaneous adverse reaction. An important gene associated with Erythema Multiforme Major is HLA-B (Major Histocompatibility Complex, Class I, B). The drugs Gabapentin and Phenytoin have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes.

Sources

Related Diseases for Erythema Multiforme Major

About this section

Diseases related to Erythema Multiforme Major via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)
# Related Disease Score Top Affiliating Genes
1 erythema multiforme 11.8
2 severe cutaneous adverse reaction 10.5
3 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 10.5
4 exanthem 10.4
5 herpes simplex 10.3
6 stevens-johnson syndrome/toxic epidermal necrolysis 10.3
7 vascular disease 10.2
8 neutropenia 10.1
9 skin disease 10.1
10 bullous pemphigoid 10.1
11 pemphigus 10.1
12 autoimmune disease 10.0
13 major affective disorder 1 10.0
14 renal cell carcinoma, nonpapillary 10.0
15 immune deficiency disease 10.0
16 yemenite deaf-blind hypopigmentation syndrome 10.0
17 meningioma, radiation-induced 10.0
18 meningioma, familial 10.0
19 chlamydia pneumonia 10.0
20 pemphigus gestationis 10.0
21 disseminated intravascular coagulation 10.0
22 chlamydia 10.0
23 spinal meningioma 10.0
24 cicatricial pemphigoid 10.0
25 allergic hypersensitivity disease 10.0
26 quadriplegia 10.0
27 pemphigoid gestationis 10.0
28 thrombocytopenia 10.0
29 focal epilepsy 10.0
30 systemic scleroderma 10.0
31 secretory meningioma 10.0
32 lymphoplasmacyte-rich meningioma 10.0
33 pneumonia 10.0
34 conjunctivitis 10.0
35 acquired immunodeficiency syndrome 10.0
36 epilepsy with generalized tonic-clonic seizures 10.0
37 impetigo 10.0
38 herpes zoster 10.0
39 crohn's disease 10.0
40 alopecia areata 10.0
41 alopecia 10.0
42 neisseria meningitidis infection 10.0
43 bullous impetigo 10.0
44 acute liver failure 10.0

Graphical network of the top 20 diseases related to Erythema Multiforme Major:



Diseases related to Erythema Multiforme Major
Sources

Symptoms & Phenotypes for Erythema Multiforme Major

About this section
Sources

Drugs & Therapeutics for Erythema Multiforme Major

About this section

Drugs for Erythema Multiforme Major (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
2
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
3
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
4
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
7 Molgramostim Investigational Phase 4 99283-10-0
8 Pharmaceutical Solutions Phase 4
9 Ophthalmic Solutions Phase 4
10 Psychotropic Drugs Phase 4
11 Anticonvulsants Phase 4
12 Analgesics, Opioid Phase 4
13 Analgesics, Non-Narcotic Phase 4
14 Analgesics Phase 4
15 Excitatory Amino Acid Antagonists Phase 4
16 Anti-Anxiety Agents Phase 4
17 Hypolipidemic Agents Phase 4
18 Lipid Regulating Agents Phase 4
19 Antimetabolites Phase 4
20 Sodium Channel Blockers Phase 4
21 Diuretics, Potassium Sparing Phase 4
22 Anti-Arrhythmia Agents Phase 4
23 Neurotransmitter Agents Phase 4
24 Adrenergic Agents Phase 4
25 Adrenergic Antagonists Phase 4
26 Sympatholytics Phase 4
27 Adrenergic beta-Antagonists Phase 4
28
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
29
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
30
Lesinurad Approved, Investigational Phase 3 878672-00-5 53465279
31
Efavirenz Approved, Investigational Phase 3 154598-52-4 64139
32
Etravirine Approved Phase 3 269055-15-4 193962
33
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
34
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
35
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
36
tannic acid Approved Phase 2, Phase 3 1401-55-4
37 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
38
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
39
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
40
Azithromycin Approved Phase 2, Phase 3 83905-01-5 447043 55185
41
Lopinavir Approved Phase 2, Phase 3 192725-17-0 92727
42
Hydrocortisone Approved, Vet_approved Phase 2, Phase 3 50-23-7 5754
43
Hydrocortisone acetate Approved, Vet_approved Phase 2, Phase 3 50-03-3
44
Hydroxychloroquine Approved Phase 2, Phase 3 118-42-3 3652
45
Ritonavir Approved, Investigational Phase 2, Phase 3 155213-67-5 392622
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
47
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
48
Maraviroc Approved, Investigational Phase 2, Phase 3 376348-65-1 3002977
49
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
50
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
2 A Prospective, Randomized, Placebo-controlled Trial of Pre-transplant and Prompt Post-transplant Treatment With Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation Completed NCT01915082 Phase 4 Azithromycin;Ora-Plus
3 Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin on Post-operative Opioid Use and Patient Satisfaction Completed NCT01977937 Phase 4 Gabapentin 250mg/5mL NDC:59762-5025-01;Simple Syrup
4 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
5 Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction Completed NCT02291796 Phase 4 Bezafibrate
6 Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
7 Transdermal Lidocaine Patch for Post-Cesarean Pain Control for Women With Obesity: a Single-blind Randomized Controlled Trial Active, not recruiting NCT03810235 Phase 4 Transdermal Lidocaine Patch;Transdermal Hydrocolloid Placebo Patch
8 A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Not yet recruiting NCT02347111 Phase 4 Flecainide;Sotalol
9 Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
10 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
11 Efficacy of Cultivated Corneal Epithelial Stem Cell for Ocular Surface Reconstruction Completed NCT01237600 Phase 2, Phase 3
12 Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Completed NCT00346450 Phase 3
13 A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor Completed NCT01508702 Phase 3 lesinurad;Placebo
14 A Phase III, Double Blind, Mulit-centre, Randomised Placebo Controlled, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirez With Continuing Central Nervous System (CNS) Toxicity to TMC125. Completed NCT00792324 Phase 3 Etravirine;Efavirenz
15 Randomised Evaluation of COVID-19 Therapy Recruiting NCT04381936 Phase 2, Phase 3 Lopinavir-Ritonavir;Corticosteroid;Hydroxychloroquine;Azithromycin;Tocilizumab
16 Maraviroc to Augment Rehabilitation Outcomes After Stroke Recruiting NCT03172026 Phase 2, Phase 3 Maraviroc 300 mg;Placebo 300 mg
17 NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT02987257 Phase 3 Harmonized supportive care;Cyclosporine 5 mg/kg bid days 0-14;Etanercept 50 mg sc day 0 and day 3
18 Lamictal in the Treatment of Post-Herpetic Neuralgia-A Safety, Efficacy,Randomized, Double Blind, Placebo Controlled, Cross-Over Study Terminated NCT00295776 Phase 2, Phase 3 Lamictal in the treatment of Post-Herpetic Neuralgia
19 The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
20 Evaluation the Effect of Amniotic Membrane Extract Eye Drop (AMEED) on Human Corneal Epithelium Healing (Phase I and II Clinical Trial) Completed NCT02746848 Phase 1, Phase 2
21 Comparison of Standard Versus Double Dose of Amoxicillin in the Treatment of Non-Severe Pneumonia in Children Aged 2-59 Months: A Multi-Centre Randomized Double Blind Controlled Trial in Pakistan Completed NCT00130013 Phase 1, Phase 2 Oral Amoxicillin
22 Palifermin Treatment of Toxic Epidermal Necrolysis Terminated NCT02037347 Phase 1, Phase 2 Palifermin
23 Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis Withdrawn NCT01256489 Phase 1, Phase 2 Infliximab
24 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
25 Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis Withdrawn NCT00372723 Phase 2 Remicaide (infliximab)
26 A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN) Withdrawn NCT02319616 Phase 1, Phase 2 Clobetasol 0.05% ointment;Placebo
27 Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of Ocular Surface Reconstruction Completed NCT00344201 Phase 1
28 Topical Infliximab for the Treatment of Sterile Corneal Melt Recruiting NCT02987686 Phase 1 Topical Infliximab
29 Platelet Rich-plasma in Management of Chronic Multiple Oral Ulcers Not yet recruiting NCT03878771 Phase 1 Dermovate cream in Orabase
30 Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction and Correlation With Disease Severity. Unknown status NCT03166241
31 Comparison of Corneal Epitheliotropic Factors in Autologous Serum Eye Drops Between Nonautoimmune Dry Eye and Stevens-Johnson Syndrome With Dry Eye Unknown status NCT01122303
32 A Prospective Study to Prove the Usefulness of HLA-B*5801 Screening Test for the Prevention of Allopurinol-induced Severe Cutaneous Adverse Reaction in Patient With Chronic Kidney Disease Unknown status NCT03046914
33 Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Unknown status NCT02795143 Isotretinoin
34 The Use of Pentacam in Assessment of Corneal Changes After Pterygium Excision Unknown status NCT03304366
35 The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation Unknown status NCT00696982 sitagliptin;glibenclamide
36 Salivary Gland and Labial Mucous Membrane Transplantation in the Treatment of Severe Symblepharon and Dry Eye in Patients With Stevens-Johnson Syndrome. Completed NCT01178242
37 Stevens-Johnson Syndrome Associated With Antimicrobial Completed NCT00844038
38 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions (SCAR) Completed NCT01276314 anti- TNF-a;Prednisolone
39 A Prospective Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of ARGOS-IO System in Patients Undergoing Implantation of a Boston Keratoprosthesis (BKPro) Completed NCT02945176
40 Evaluation of Immune Responses to Different Antigens in Non Infectious Ocular Inflammatory Diseases Completed NCT00357071
41 Safety and Effectiveness of a Laboratory Intervention to Effectively NOT Treat Asymptomatic Bacteriuria (SALIENT-A) Completed NCT03445312
42 Adverse Cutaneous Drug Reactions Collection of Clinical Data and Biological Samples Recruiting NCT03659227
43 Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients Recruiting NCT04252651
44 The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Recruiting NCT03839069
45 The Multicenter Registry of Patients With Severe Cutaneous Adverse Reactions Among Tertiary Medical Institutes in Thailand Recruiting NCT02574988
46 The Effects of Autologous Simple Limbal Epithelial Transplantation. Recruiting NCT04021875
47 The Effects of Allogeneic Simple Limbal Epithelial Transplantation Recruiting NCT04021134
48 HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions: a Multicenter Clinical Study Recruiting NCT03184597
49 An Exploratory Case-Control Study of Genetic and Clinical Factors for Serious Cutaneous Reactions Among Users of Eslicarbazepine Acetate Recruiting NCT02520557
50 Corneal Collagen Crosslinking to Increase the Resistance of the Graft Used as a Support for the Boston Keratoprosthesis Type I Against Corneal Melting Recruiting NCT03041883

Search NIH Clinical Center for Erythema Multiforme Major

Sources

Genetic Tests for Erythema Multiforme Major

About this section
Sources

Anatomical Context for Erythema Multiforme Major

About this section

MalaCards organs/tissues related to Erythema Multiforme Major:

40
Skin, Eye, Testes, T Cells, Liver, Lung, Salivary Gland
Sources

Publications for Erythema Multiforme Major

About this section

Articles related to Erythema Multiforme Major:

(show top 50) (show all 3552)
# Title Authors PMID Year
1
Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. 6 61
29392710 2018
2
Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. 6 61
24597466 2014
3
HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. 61 6
23588310 2013
4
Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. 6 61
23232549 2013
5
Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. 61 6
21428768 2011
6
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. 61 6
16538176 2006
7
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. 6 61
15743917 2005
8
Medical genetics: a marker for Stevens-Johnson syndrome. 61 6
15057820 2004
9
The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. 6 61
8006430 1994
10
Altered levels of complement components associated with non-immediate drug hypersensitivity reactions. 61
31795786 2020
11
Long-term outcomes of amniotic membrane treatment in acute Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
32200005 2020
12
Highlights from the 2nd Biennial Stevens Johnson syndrome symposium 2019: SJS/TEN from Science to Translation. 61
31785388 2020
13
Alteplase treatment for massive lung atelectasis in a child with severe bronchiolitis obliterans complicating Stevens-Johnson syndrome. 61
32324952 2020
14
Expression of prostaglandin E2 receptor 3 in the eyelid epidermis of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
31000507 2020
15
Ectopic sebaceous glands of Gibsan in eyelid margin- A novel manifestation in Stevens Johnson Syndrome & proposed nomenclature based on an observational case series. 61
32194257 2020
16
Treatment for oral lesions in pediatric patients with Stevens-Johnson's syndrome: A case report and literature review. 61
31923328 2020
17
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children With Non-Hodgkin Lymphoma. 61
32576784 2020
18
Clinical clues predictive of Stevens-Johnson syndrome as the cause of chronic cicatrising conjunctivitis. 61
31630093 2020
19
Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. 61
32151629 2020
20
Differences in treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis at burn centers and non-burn centers. 61
32498082 2020
21
Acute pancreatic injuries: A complication of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immune cell activation. 61
32561372 2020
22
Successful use of rifampin in a patient with Stevens-Johnson syndrome to rifabutin. 61
32169513 2020
23
Stevens-Johnson syndrome triggered by Levetiracetam-Caution for use with Carbamazepine. 61
32540638 2020
24
Stevens-Johnson Syndrome Secondary to Doxycycline Treatment in a Teenage Boy. 61
32574716 2020
25
[Advances in understanding of the pathophysiology of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis)]. 61
32253008 2020
26
Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review. 61
32052409 2020
27
Long-term Progression of Ocular Surface Disease in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 61
32028281 2020
28
A pediatric case of Stevens-Johnson syndrome/toxic epidermal necrolysis with rapid response to intravenous cyclosporine. 61
32509946 2020
29
Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China. 61
31898979 2020
30
Erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis - diagnosis and treatment. 61
32469468 2020
31
An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. 61
32510242 2020
32
Association of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients. 61
31896765 2020
33
Clinical trial to evaluate the therapeutic benefits of limbal-supported contact lens wear for ocular sequelae due to Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
32513522 2020
34
Reply to: "The age of procalcitonin: Potential pitfalls in critically ill patients with SJS/TEN. A comment on 'Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients'". 61
32092373 2020
35
The age of procalcitonin: potential pitfalls in critically ill patients with SJS/TEN. A comment on "Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients". 61
32092376 2020
36
The Association Between Concurrence of Infection and the Onset of Severe Eruption or Liver Injury in Patients Using Antipyretic Analgesics: A Matched, Nested Case-Control Study. 61
32521061 2020
37
Burn center admissions of patients with autoimmune rheumatic diseases: clinical characteristics and outcomes. 61
32507914 2020
38
General characteristics, economic burden, causative drugs and medical errors associated with medical damage litigation involving severe cutaneous adverse drug reactions in China. 61
32516456 2020
39
Traditional and advanced therapeutic modalities for wounds in the paediatric population: an evidence-based review. 61
32530778 2020
40
Fixed Drug Eruptions: An Update, Emphasizing the Potentially Lethal Generalized Bullous Fixed Drug Eruption. 61
32002848 2020
41
Mycoplasma Pneumoniae Induced Rash and Mucositis (MIRM): A Longitudinal Perspective and Proposed Management Criteria. 61
32574770 2020
42
Ventilatory support in Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. 61
32412819 2020
43
RIP3 as a diagnostic and severity marker for Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
31954192 2020
44
Upper airway involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
31591001 2020
45
The effects of systemic cyclosporine in acute Stevens-Johnson syndrome/toxic epidermal necrolysis on ocular disease. 61
32445836 2020
46
Erythema Multiforme Versus Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Subtle Difference in Presentation, Major Difference in Management. 61
32373930 2020
47
Two False Negative Test Results in a Symptomatic Patient with a Confirmed Case of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Suspected Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). 61
32455090 2020
48
Treatment of Oculoplastic and Ocular Surface Disease in Eyes Implanted with a Type I Boston Keratoprosthesis in Southern China: A Retrospective Study. 61
32436025 2020
49
Toxic epidermal necrolysis syndrome induced by tigecycline: a case report. 61
32400243 2020
50
Genetic variants associated with T cell-mediated cutaneous adverse drug reactions: A PRISMA-compliant systematic review-An EAACI position paper. 61
31899808 2020
Sources

Variations for Erythema Multiforme Major

About this section

ClinVar genetic disease variations for Erythema Multiforme Major:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HLA-B HLA-B*15:02undetermined variant risk factor 14909
2 HLA-B HLA-B, HLA-B*5801undetermined variant risk factor 14911
Sources

Expression for Erythema Multiforme Major

About this section
Search GEO for disease gene expression data for Erythema Multiforme Major.
Sources

Pathways for Erythema Multiforme Major

About this section
Sources

GO Terms for Erythema Multiforme Major

About this section
Sources

Sources for Erythema Multiforme Major

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....